← Leaderboards
Ryan Eugene Temel
Wake Forest University Health Sciences
$5,221,164
Attributed
$5,696,752
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $767.9K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,696,752 · 5
By mechanism
R01$4,359,334 · 2
R00$743,227 · 1
R21$420,750 · 1
K99$173,441 · 1
Top collaborators
- Scott Michael Damrauer1 shared
- Hong Shen Lu1 shared
Others in their field
Top investigators on “Cholesterol”
- Leon J Thal · University Of California San Diego$54,467,813
- Daniel James Rader · University Of Pennsylvania$44,733,174
- Alan Richard Tall · Columbia University Health Sciences$38,760,184
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$38,718,698
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$34,107,220
- Stanley L Hazen · Cleveland Clinic Foundation$28,886,562
Research focus
CholesterolNonhuman PrimateGenesMonkeysCercopithecus PygerythrusApolipoproteinsMediatingProteinsLiverHepaticHigh Density LipoproteinsAffectHigh Density Lipoprotein CholesterolCoronary Heart DiseaseRisk FactorsInflammationPreventAntisense OligonucleotidesAtherosclerosisLipidsCatabolismCessation Of LifeLipaseLipoprotein Lipase
Grant awards (13)
Triglyceride-rich lipoproteins and abdominal aortic aneurysm growth and progression$713,382
R01 · FY2025 · HL
Targeting microRNA-33 to reduce intracranial atherosclerosis and other neurovascular hallmarks of vascular cognitive impairment and dementia$420,750
R21 · FY2019 · NS · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$721,178
R01 · FY2017 · HL · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$713,949
R01 · FY2016 · HL · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$53,999
R01 · FY2016 · HL · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$724,972
R01 · FY2015 · HL · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$716,714
R01 · FY2014 · HL · contact PI
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates$715,140
R01 · FY2013 · HL · contact PI
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates$246,524
R00 · FY2011 · HL · contact PI
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates$247,703
R00 · FY2010 · HL · contact PI
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates$249,000
R00 · FY2009 · HL · contact PI
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates$85,709
K99 · FY2008 · HL · contact PI
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates$87,732
K99 · FY2007 · HL · contact PI